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Abstract
Background: The outcome measures most frequently used in studies on the effectiveness of migraine treatment are
whether the patient is free of pain, nausea, and free of photophobia/phonophobia within two hours. However, no patient-
centred outcome measures are available. Therefore, we performed an online Delphi procedure to compile a list of outcome
measures deemed most important to migraine patients.
Methods: From a large database of migraine patients, we randomly selected 150 males and 150 females patients. We asked
the open-ended question: ‘If a new medicine was developed for migraine attacks, what would you wish the effect of this
medication to be?’ In the second and third rounds, we presented the answers of the first round and asked the patients to
rate the importance of each item.
Results: The initial response rate was 56% (n = 169). In the subsequent rounds the response rates were 90% (n = 152), and
97% (n = 147), respectively. Patients wanted their attack medication to treat the headache within 30 min, to prevent the
attack from getting worse, to ensure they could function properly within 1 h, and prevent the recurrence of symptoms
during the same day.
Conclusions: The currently used outcome measures in migraine research do not sufficiently reflect the wishes of patients.
Patients want the medication to work faster, to take away pain at an earlier stage, to make them able to function properly
quickly, and to prevent recurrence. These aspects should be considered in future evaluation of new attack medication for
migraine.
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Introduction
The most important outcome measure used in studies on the
effectiveness of migraine treatment is whether the patient is pain
free within two hours after taking the medicine [1]. Other
symptoms assessed in this evaluation are nausea/vomiting and
photophobia and phonophobia. The choice for these outcome
measures is based on consensus among migraine specialists [1].
Despite claims that these outcome measures reflect the expecta-
tions of migraine patients, patients’ wishes have only been
explored by asking their opinion about the currently used outcome
measures [2,3]. To our knowledge, migraine patients have not
been asked to add what they consider important themselves.
Therefore, it can be questioned whether the currently used
outcome measures in migraine research sufficiently reflect what is
most relevant to the patients [4].
The importance of outcome measures relevant to patients was
the rationale to start a Delphi study. The Delphi consensus
method is commonly used within the health and social sciences to
determine to what extent people agree about a given issue, or to
transform opinion into group consensus. It is an iterative
multistage process with a flexible approach to data collection
most often in a series of structured questionnaires (rounds). In our
study, the ‘experts’ (participants) anonymously completed the
questionnaires in three rounds. The initial questionnaire collected
qualitative comments, which were reported back to the partici-
pants in the second round in a quantative form. After the second
round, the responses were summarized and reported to the
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participants in the third round [5,6] This method has previously
been used in the development of outcome measures [7].
In the present study we asked migraine patients to formulate
their own outcome measures, with the aim to compile a short list
of outcome measures that they considered most important. Also,
we aimed to establish to what extent patients agree with the
commonly used outcome measures. A similar project in patients
with rheumatoid arthritis led to surprising results and the
development of new outcome measures, that are now recom-
mended in drug trials worldwide [8].
Methods
We performed a Delphi procedure with web-based question-
naires that allowed patients to give their input over three rounds.
In the first round we made an inventory of all possible opinions
and we compiled a list of candidate items. In the second and third
rounds we asked patients to evaluate these items.
Patient panel
For this Delphi project, we randomly selected 150 male and 150
female patients from the Leiden University Medical center Neuro
Analysis (LUMINA) database. We stratified patients for sex and
treatment location (primary care or secondary care) in order to be
able to detect differences between these groups of patients after
answering the questions.
The LUMINA database includes over 54,000 adult migraine
patients [9]. Of all the patients in this database, 87% has been
diagnosed as migraine patient by a physician and 13% were self-
reported migraineurs Of all patients 70% uses triptans. Upon
entering the cohort, patients have to fill in an extensive
questionnaire. In addition to questions necessary to accurately
diagnose migraine, the questionnaire also includes items on
demographic factors, acute and prophylactic headache medication
use, and migraine attack frequency. Migraine diagnoses are
established using a validated questionnaire based on the Interna-
tional Classification of Headache Disorders (ICHD-III) [10].
Ethics statement
The LUMINA project has been approved by the Medical Ethics
Committee of the LUMC. All participants of the LUMINA study
provided written informed consent.
Delphi questionnaires
Patients were sent an invitation by email to fill in three web-
based questionnaires during a 6-month period. Figure 1 presents
the questions asked in the consecutive rounds. The exact content
of the questionnaires can be found in Appendix S1.
Round 1. First, we asked patients to provide information
about their current headache status: number of migraine attacks
per month, duration of migraine attacks, number of headache days
per month, recurrence, and medication use.
Second, we posed two open-ended questions:
1. What do you find most bothersome about having a migraine
attack?
2. If a new medicine was developed against migraine attacks,
what would you wish the effect of this medication to be?
Patients were asked to list a minimum of three and a maximum
of five answers, and to rate these answers on a 5-point Likert scale
(from 1=not important, to 5 = very important).
We then grouped the answers according to the presence of
strong similarity. During this process, we followed an inductive
method, i.e. answers were examined and those considered to be
more or less the same were grouped as one item. No fixed number
of items was set beforehand, in order to accommodate all new
opinions. The answers were grouped by two of the authors (AS
and VdG) separately, to ensure independence of assessments. Any
discrepancies were resolved through a discussion with two other
authors (ML and DK), who also checked whether they agreed with
the items as formulated by AS and VdG.
Third, we asked patients to rate the relevance of the outcome
measures currently used in clinical trials on a 5-point Likert scale
(from 1=not important, to 5 = very important). We extracted
these outcome measures from the most recent guideline for
controlled migraine drug trials and from a recently published
questionnaire on the evaluation of migraine treatment [1,11].
Patients were asked not to rate a listed outcome measure if they
had not experienced it themselves.
The three questions in Round 1 were presented one by one,
without the possibility to look back and change answers to the
earlier questions. Thus, patients answered the open-ended
questions (exploration of patients’ opinions) without knowledge
of the currently used outcome measures that were mentioned in
the last step (existing criteria). In this way we ensured that
participants were not informed about the content of the currently
used outcome measures when answering the open-ended question.
Round 2. In the Round 2 we presented to the patients the
categorized answers to the open-ended question ‘If a new
medicine was developed against migraine attacks, what would
you wish the effect of this medication to be?’ and asked to choose
the five most important items and evaluate these on a 5-point
Likert scale (from 1=not important, to 5 = very important). The
respondents were encouraged to comment on the list of items
presented to them and to add any items that they felt had been left
out.
Items from Round 2 were ranked according to the weight-
frequency product, that was calculated based on the returned
questionnaires, by multiplying the number of times an item was
suggested byits mean weight (calculated based on the ranking of
items on the Likert scale).
Round 3. In Round 3 we included the items from the top 15
of the male responses and from the top 15 of the female responses.
First, we asked participants if they agreed with the way we
combined the items that, in our opinion, reflected the same or very
similar content.
Second, we asked patients to select 5 items of the randomly
presented list that they considered most crucial in the evaluation of
the effect of acute headache medication. We asked patients to
value these 5 items by distributing 10 points over these items, such
that the item they considered most important was given the
highest number of points. Third, we asked participants to indicate
how quickly (time to onset) they would want the effect to occur
(but only for the symptoms they had experienced themselves).
Results
Participants
Figure 2 presents the flow of participants through the study. Of
the 300 patients, the first questionnaire (Round 1) was returned by
169 (56%) patients. Participants and non-participants were
compared on the following characteristics available from the
LUMINA database: age, educational level, headache subtype,
headache frequency, medication use, educational level, anxiety
scores, and depression scores (data not shown). Of the 169
participants in Round 1, 55% were women (n = 93) and 45% were
men (n= 76). There were no significant differences between
Delphi Study on Outcomes for Effectiveness Studies in Migraine
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participants and non-participants on any of the other character-
istics.
Response rates (as percentage of the respondents in the previous
round) in the consecutive rounds were high, i.e. 90% in Round 2
and 97% in Round 3.
Figure 1. Contents of the three consecutive Delphi questionnaires. Grey boxes: contents of questionnaires. White boxes: actions by
researchers.
doi:10.1371/journal.pone.0098933.g001
Figure 2. Flowchart of panel member participation.
doi:10.1371/journal.pone.0098933.g002
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Round 1
Baseline characteristics. The baseline characteristics of
participants derived from the first Delphi questionnaire are shown
in Table 1.
First Delphi question: Most bothersome aspects of having
migraine attacks. The most frequently mentioned bothersome
aspects of having a migraine attack were headache pain (62%) and
the impact of migraine headaches on daily life (53%). Answers to
this question were similar for male and female respondents. An
overview of all answers can be found in Table S1.
Second Delphi question: Patients’ wishes concerning the
effect of attack medication. The effects most frequently
wished for were that the medication would take away the
headache (18%) and that the medication would have no adverse
effects (15%). Although we were investigating the effect that
patients wished their attack medication to have, some participants
spontaneously mentioned that they thought it was important that
the cause of their migraine was treated (5th and 6th place in
ranking order) and that the medication had no negative effects on
the long term (6th and 7th place in ranking order). These items
focused on migraine-related aspects rather than on the direct effect
of migraine on the patient. Accordingly, these two items were
included in the second round to give patients the opportunity to
indicate how important they rated these particular aspects.
However, after the second round these types of items were
excluded, because our final aim was to compile a short list of
outcome measures for migraine research.
Evaluation of currently used outcome measures. The
ranking of the currently used outcome measures is presented in
Table S2. Patients considered the following outcome measures to
be the most important for them: decrease of headache, time to
effect, no relapse within one day, reliability of medication, and
how soon they are able to resume normal activities.
Round 2
Second Delphi question: Patients’ wishes concerning the
effect of attack medication. After the answers to the second
Delphi question were grouped into 36 categories we presented
them to the patient panel again and asked to choose the five most
important items and evaluate these on a 5-point Likert scale (from
1=not important, to 5 = very important). The results and the
ranking of the items based on can be found in Table S3. The
highest ranked items were ‘take away the headache’ and ‘prevent
the attack from carrying on’.
As mentioned before, after Round 2 we excluded the items that
items focused on migraine-related aspects rather than on the direct
effect of migraine on the patient. The excluded items were: ‘Have
no or fewer side-effects’, ‘Have no negative effects in the long
term’, ‘Treat the cause’, ‘Work as effectively each time’, ‘Not be
too expensive’, and ‘Is easy to take in’. Also, excluded was the item
‘Work fast’ as information on the time to effect (speed of onset) was
addressed in a separate question.
Of the candidate items, four pairs resembled each other to a
considerable extent and were therefore combined. For example,
we combined the answers ‘I want the medicine to clear my head’
and ‘I want the medicine to enable me to think clearly again’ into
‘I want the medicine to enable me to think clearly again’. In the
third round we explicitly asked participants if they agreed with our
decisions concerning the way these items were combined.
Round 3
Combination of items. More than 60% of participants
agreed with our combination of the four pairs of similar items.
Second Delphi question: Patients’ wishes concerning the
effect of attack medication. The final results of the Round 3
are presented in Table 2. The items considered most important
were: take away the headache, prevent the attack from carrying
on, no relapse within one day, and let the patient function properly
again.
Table 1. Characteristics of panel members (N= 169).
Characteristics
% female 55.0%
Age in years, median (IQR) 47 (40–57)
Years of fulltime education 13.8 (3.6)
HADS total score 11.0 (6.4)
% $1–4 attacks per month 57.4%
% $1–4 days per month 74.6%
Number of headache days per month 9.2 (7.8)
Number of migraine headache days per month 7.1 (6.3)
% treatment by general practitioner 48%
% treatment by neurologist 33%
Use of a simple analgesic*, days per month 5.37 (6.4)
Use of ergotamine per month, days per month 0.04 (0.33)
Use of triptan per month, days per month 5.3 (5.4)
Use of medication per month, days per month 6.9 (5.5)
% use of prophylaxis 37%
Values are means (SD) unless stated otherwise.
HADS=Hospital Anxiety and Depression Scale.
* Paracetamol, NSAID, or saridon.
doi:10.1371/journal.pone.0098933.t001
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The ranking order for the five highest ranked items did not
differ between male and female participants (data not shown).
Female participants ranked nausea higher compared to male
participants (8th and 15th place in ranking order, respectively).
Male participants ranked problems with vision higher compared to
female participants (9th and 13th place in ranking order,
respectively). These differences are related to a difference in the
incidence of these symptoms between male and female partici-
pants (i.e. 25.0% of females always experiences nausea, compared
to 15.0% of men; 17.5% of females always experience problems
with vision compared to 26.9% of men).
The ranking order of the five highest ranked items did not differ
between patients who were treated by a neurologist and those not
treated by a neurologist (data not shown). Differences lower in the
ranking order were also related to a difference in the incidence of
symptoms between these two groups.
Time to effect. The results of the question on speed of onset
are presented in Table 3. According to the respondents, the
headache pain, the pressing or thumping feeling, and the
accompanying symptoms should have disappeared within
30 min. They accepted a slightly longer induction time of 1 h,
for being able to function properly and being able to think clearly
again, not feeling lethargic and tired, and being cured of their neck
ache.
Discussion
Main results
This Delphi study shows that the outcome measure ‘pain free
within 2 hours’ on its own does not sufficiently reflect what is
important to migraine patients. Patients want their attack
medication to relieve the headache within 30 min, rather than
the currently used criterion ‘pain free within two hours’. They also
want the medication to prevent the attack from carrying on, to
prevent recurrence, and allow them to function properly within
1 h. This applies to both male and female patients, and to patients
treated by a neurologist and not treated by a neurologist.
Strengths and weaknesses
This is the first study in which migraine patients were
specifically asked what they consider important with respect to
the development of new attack medication for migraine, in a
setting where they were not influenced by their fellow patients
and/or an interviewer. This allowed them to freely form and
express their personal opinions. Also, the Delphi design enabled us
to start with an explorative open-ended question in the first round
and, subsequently, to ask patients to evaluate the answers that
were given and specify the desired ‘time to effect’ in the second
and third rounds. We consider this a major and distinctive strength
and of the present study. In addition, the present study is
representative for patients from both general practice and
secondary/tertiary care.
The study also has some limitations. First, the population might
be somewhat higher educated than the migraine population in
general, as they had to fill in questionnaires via internet. These
patients might have more insight about migraine and headaches,
which could have influenced the results. Also, patients who
respond well to their current medication and had less headaches
might have answered questions differently from patients who did
not respond well to their medication or had severe headaches.
Secondly, inherent to the study is that subjective choices had to be
made when formulating items and constructing the questionnaires.
However, this was carefully performed by i) involving a health
psychologist with no background in migraine research as to enable
more objective decision-making, ii) categorising the answers to the
open-ended questions independently, and iii) requiring consensus
from all authors when designing the questionnaires. Thirdly, the
Delphi procedure is a consensus method in which opinions of
individual participants that are not supported by others will not
come up in the final result. In order to ensure that no valuable
opinion that was supported by many participants would be missed,
we fed back all opinions that were expressed in Round 1 to the
participants in Round 2. In this way, all patients had the possibility
to reflect on the suggestions of co-participants which they had not
thought of themselves.
Table 2. Final results of second Delphi question (third round).
Ranking Outcome measure N
Mean item
weight (SD)
Frequency-weight
product*
1 take away the headache 121 3.36 (1.52) 407
2 prevent the attack from carrying through 100 2.55 (1.38) 255
3 make sure no other attack follows within a few hours or within a day 83 1.90 (0.96) 158
4 let me function properly again 83 1.64 (1.04) 136
5 clear my head 56 1.41 (0.11) 79
6 take away the pressing or thumping feeling 43 1.61 (0.19) 69
7 take away the nausea 49 1.35 (0.13) 66
8 take away the problems with vision (light flashes, hazy vision, double vision) 30 2.17 (0.25) 65
9 take away the sense of illness during a headache attack 41 1.41 (0.16) 58
10 take away the neck pain 35 1.57 (1.18) 55
11 take away the tiredness 44 1.00 (0.11) 44
12 take way the loss of function (problems with speech, tingling or loss of power in
arms/legs)
23 1.70 (0.25) 39
13 take away the persistent headache after the headache attack 27 1.19 (0.16) 32
Items considered most important by the participants (N = 147).
* Weight frequency product: weight multiplied by the number of times it is mentioned.
doi:10.1371/journal.pone.0098933.t002
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Comparison literature
A telephone survey of migraine patients among the general
population showed that migraine patients rate the following items
as the most important attributes of acute migraine treatment:
complete relief of head pain, lack of recurrence and rapid onset of
pain relief. In that survey 71% of the patients wanted the pain to
be gone in less than 30 min [12]. After existing outcome measure
had been presented to our patients, this Delphi study allowed them
to suggest medication effects that they considered to be important;
this yielded two new items, i.e. ‘Prevention of worsening of the
attack’ and ‘The ability to function properly again within 1 hour’.
It is reported that most migraine patients (54%) do not notice
any benefit in the first hour after taking headache medication [13].
Remarkably, although the wish for a faster effect of attack
medication was already expressed by patients in a study published
in 1999 [12], the outcome measures used in the evaluation of
medication have not yet been altered.
Conclusions
The currently used outcome measures in migraine research do
not sufficiently reflect the expectations of migraine patients. The
present study shows that patients wish their headache to be taken
away within 30 min. It seems that, until now, research on
migraine medication has been guided by what was considered
possible and not by the actual wishes/expectations of migraine
patients. The results of the present study clearly indicate that
treatment should focus on: being pain free rapidly, preventing the
migraine from becoming worse, preventing the recurrence of
migraine, restoring proper function and permitting patients to
think clearly again within an hour. Future research should aim to
develop an outcome measure that combines all these aspects and
thereby enable measurement of what migraine patients find most
important.
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